About

Onconostic Technologies / 3N Diagnostics is leading precision oncology diagnostics with its versatile VERESCA FOXC1 test, an immunohistochemistry (IHC) tumor biopsy assay which identifies FOXC1 expression levels to guide personalized treatment selection for hormonal therapy, chemotherapy, and immunotherapy. By taking tumor plasticity into account, undetected by other tests, the VERESCA test based approach has been able to achieve far greater accuracy in predicting drug efficacy in head-to-head comparison studies.

Oncologists will order the VERESCA test on a patient's tumor biopsy to identify those patients who are at heightened risk of suffering metastatic recurrence and will benefit from life-saving chemotherapy an targeted therapies. Drug companies will use the test as a Drug-Companion diagnostic to significantly improve drug regulatory filing and treatment success rates.

Remarkable life extension has been demonstrated in multiple prospective and retrospective trials and the product has been validated in over 17,000 cancer patients. Additional indications will be added to the CE Mark as clinical trials utilizing the test are completed, and FDA approval will also be sought on a pan-tumor basis. The clinically validated test in now commercially available to hospitals and oncologists.